[go: up one dir, main page]

IN2013CN09704A - - Google Patents

Info

Publication number
IN2013CN09704A
IN2013CN09704A IN9704CHN2013A IN2013CN09704A IN 2013CN09704 A IN2013CN09704 A IN 2013CN09704A IN 9704CHN2013 A IN9704CHN2013 A IN 9704CHN2013A IN 2013CN09704 A IN2013CN09704 A IN 2013CN09704A
Authority
IN
India
Prior art keywords
mirabegron
preparation
form crystal
amorphous
aspects
Prior art date
Application number
Inventor
Vishweshwar Peddy
Rajesham Boge
Original Assignee
Reddys Lab Ltd Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddys Lab Ltd Dr filed Critical Reddys Lab Ltd Dr
Priority to IN9704CHN2013 priority Critical patent/IN2013CN09704A/en
Publication of IN2013CN09704A publication Critical patent/IN2013CN09704A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Liquid Crystal Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Aspects of the present invention relate to amorphous form of mirabegron amorphous solid dispersion of mirabegron process for its preparation processes for preparation of a form crystal and ß form crystal of mirabegron and pharmaceutical composition thereof.
IN9704CHN2013 2011-05-18 2012-05-17 IN2013CN09704A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN9704CHN2013 IN2013CN09704A (en) 2011-05-18 2012-05-17

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1678CH2011 2011-05-18
US201161502911P 2011-06-30 2011-06-30
IN9704CHN2013 IN2013CN09704A (en) 2011-05-18 2012-05-17
PCT/IN2012/000356 WO2012156998A2 (en) 2011-05-18 2012-05-17 Amorphous mirabegron and processes for crystal forms of mirabegron

Publications (1)

Publication Number Publication Date
IN2013CN09704A true IN2013CN09704A (en) 2015-07-03

Family

ID=47177412

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9704CHN2013 IN2013CN09704A (en) 2011-05-18 2012-05-17

Country Status (4)

Country Link
US (1) US9283210B2 (en)
EP (1) EP2709993A4 (en)
IN (1) IN2013CN09704A (en)
WO (1) WO2012156998A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9655885B2 (en) * 2011-05-18 2017-05-23 Dr. Reddy's Laboratories Ltd. Amorphous mirabegron and processes for crystal forms of mirabegron
CN103193730A (en) * 2013-04-17 2013-07-10 苏州永健生物医药有限公司 Synthesis method of mirabegron
WO2015040605A1 (en) 2013-09-23 2015-03-26 Ranbaxy Laboratories Limited Crystalline form of mirabegron
WO2015040573A1 (en) 2013-09-23 2015-03-26 Ranbaxy Laboratories Limited Mirabegron dimethyl sulphoxide solvate and its use for the treatment of overactive bladder
WO2015044965A1 (en) 2013-09-30 2015-04-02 Megafine Pharma (P) Ltd. A process for preparation of mirabegron and alpha crystalline form thereof
ITMI20131653A1 (en) 2013-10-07 2015-04-08 Dipharma Francis Srl CRYSTALLINE FORMS OF AN ADRENERGIC AGONIST
US20170291882A1 (en) * 2014-10-01 2017-10-12 Apotex Inc. Solid Forms of Mirabegron
WO2016125074A1 (en) 2015-02-02 2016-08-11 Lupin Limited Process for preparation of polymorphic form of mirabegron
WO2016181283A1 (en) * 2015-05-11 2016-11-17 Aurobindo Pharma Ltd A PROCESS FOR THE PREPARATION OF MIRABEGRON α-FORM CRYSTALS
JP6618736B2 (en) * 2015-09-01 2019-12-11 沢井製薬株式会社 Mirabegron-containing tablet, method for producing mirabegron-containing preparation, and method for producing mirabegron-containing granulated product
FR3043555B1 (en) * 2015-11-17 2019-10-25 Centre National De La Recherche Scientifique (Cnrs) MIRABEGRON FOR THE TREATMENT OF RETINAL DISEASES
EP3184516A1 (en) 2015-12-23 2017-06-28 Enantia, S.L. Crystalline inclusion complexes of mirabegron with beta-cyclodextrin
KR101937713B1 (en) * 2017-07-14 2019-01-14 주식회사 대웅제약 Pharmaceutical formulation and preparation method for the same
KR101928987B1 (en) * 2018-08-28 2018-12-13 (주) 성운파마코피아 A New and Highly Pure Crystalline monohydrate of mirabegron, Method for Preparing or Use Thereof
CN110590699B (en) * 2019-09-29 2022-11-15 广东先强药业有限公司 Refining method of mirabegron
CN112745276B (en) * 2019-10-31 2023-10-03 四川国为制药有限公司 Crystallization method of milbegron
WO2022006336A1 (en) * 2020-07-01 2022-01-06 Jubilant Pharma Holdings Inc. Long-acting injection dosage form of beta 3 adrenoreceptor agonists
CN114539182B (en) * 2020-11-24 2024-08-09 威智医药股份有限公司 Crystal-transition solvent and application thereof, and preparation method of mirabegron alpha crystal form
KR102333167B1 (en) 2021-05-26 2021-12-01 유니셀랩 주식회사 An efficient and mass-producible Mirabegron amorphous manufacturing method
CN113773274A (en) * 2021-08-09 2021-12-10 石药集团中奇制药技术（石家庄）有限公司 Recrystallization method of mirabegron alpha crystal form raw material

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW557295B (en) * 1997-10-17 2003-10-11 Yamanouchi Pharma Co Ltd Amide derivatives or salts thereof
US7342117B2 (en) * 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
NZ539577A (en) 2002-11-07 2007-06-29 Astellas Pharma Inc Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient

Also Published As

Publication number Publication date
EP2709993A4 (en) 2015-02-25
WO2012156998A2 (en) 2012-11-22
US20140206729A1 (en) 2014-07-24
WO2012156998A3 (en) 2013-01-17
EP2709993A2 (en) 2014-03-26
US9283210B2 (en) 2016-03-15

Similar Documents

Publication Publication Date Title
IN2013CN09704A (en)
PT2744768T (en) Process for the production of ternesite clinker
IL230030B (en) Recombinant microorganism for the production of useful metabolites
GEP20247677B (en) Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
MX2015005891A (en) Polymorphic forms of suvoroxant.
IN2015KN00262A (en)
EA029539B8 (en) Pharmaceutical composition of sitagliptin
PL2785701T3 (en) Crystalline form of carbazitaxel and process for preparation thereof
HUP1100701A2 (en) Novel process for the preparation of travoprost
SG11201402949RA (en) Process for producing nutrient composition
MX2014010433A (en) Novel crystalline form of sitagliptin sulfate.
IL229647A0 (en) Novel process for the preparation of prostaglandin amides
WO2014068586A3 (en) Solid oral compositions of tolvaptan
WO2012131707A3 (en) Crystalline form of bortezomib, preparation method and pharmaceutical composition there f
EP4289819A3 (en) Process for the preparation of enantiomerically enriched 3-aminopiperidine
EP2671847A4 (en) Process for manufacture of phosphor-dispersed glass, and phosphor-dispersed glass
ZA201404385B (en) Process for the manufacture of ferrochrome
IN2014DN09451A (en)
MX2012010443A (en) Process for the preparation of 5-substituted 1-alkyltetrazoles.
MX2014009015A (en) Stable amorphous raltegravir potassium premix and process for the preparation thereof.
WO2014102759A3 (en) Process for the preparation of dasatinib and its intermediates
HUP1100177A2 (en) Recycled composition and process for preparation of it and production of regenarated, vulcanised gum
WO2013046233A3 (en) Process for the preparation of octreotide acetate
IN2013CH05282A (en)
EP2694621B8 (en) Methods for the production of fuel